ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0542

Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis

Pamela Palisoc1, Leah Vaikutis1, Ellen Model1, Morgan Omara1, Dinesh Khanna1, Eliza Pei-Suen Tsou1 and Amr Sawalha2, 1University of Michigan, Ann Arbor, MI, 2University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2021

Keywords: Epigenetics, Fibroblasts, Dermal, fibrosis, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Glycoprotein nonmetastatic melanoma protein B (GPNMB) is widely expressed on stromal cells and immune cells. It is involved in various cell functions such as cell adhesion, migration, proliferation, and differentiation, and has been implicated in various pathological conditions including cancer and neurodegenerative diseases. This membrane bound protein can be cleaved into a soluble form by ADAM10. By interacting with various cell surface receptors including CD44, soluble (s)GPNMB has the ability to activate various cell types, including fibroblasts. In this study, we set forth to determine the role of sGPNMB in fibroblast functions in systemic sclerosis (SSc).

Methods: Dermal fibroblasts were isolated from skin biopsies from healthy subjects and patients with diffuse cutaneous (dc)SSc. GPNMB expression was analyzed by qPCR, Western blotting, and immunofluorescence. sGPNMB was measured using ELISA. The effects of sGPNMB (0.01-100ng/ml) on fibroblast function were analyzed using Western blotting, proliferation, migration, and gel contraction assays. To induce a myofibroblast phenotype, normal fibroblasts were incubated with TGFβ for 72 hours. To determine the differences between groups, Mann–Whitney U test, Wilcoxon test, Kruskal–Wallis test, or two-way ANOVA were performed. P values of less than 0.05 were considered statistically significant.

Results: In dcSSc fibroblasts, GPNMB was upregulated compared to normal fibroblasts. In addition, dcSSc fibroblasts secreted higher levels of sGPNMB (147.4 ± 50.2 pg/ml vs. 84.8 ± 14.8 pg/ml, p< 0.05), partly due to increased ADAM10. sGPNMB (1 and 10 ng/ml) downregulated profibrotic genes, including collagen I and α-smooth muscle actin in dcSSc fibroblasts. In addition, it inhibited cell proliferation and gel contraction, while it had minimal effect on fibroblast migration. The anti-fibrotic effect of sGPNMB is, at least in part, mediated through CD44, as CD44 knockdown inhibits response to sGPNMB. GPNMB is regulated by its own soluble form and also through epigenetic mechanisms. TGFβ downregulated GPNMB and decreased the release of its soluble form in normal fibroblasts. We also confirmed the role of ADAM10 as the sheddase for GPNMB in dermal fibroblasts, as inhibition of ADAM10 decreased sGPNMB levels significantly after concomitant TGFβ treatment.

Conclusion: We showed for the first time, an anti-fibrotic role of sGPNMB in dcSSc fibroblasts. We also established the ADAM10-sGPNMB-CD44 axis in dermal fibroblasts; ADAM10 cleaves off the soluble form of GPNMB, which mediates its effect through CD44 in both paracrine and autocrine fashions. The futile anti-fibrotic effect in dcSSc fibroblasts might be due to the low levels of sGPNMB released from these cells (pg/ml range) vs. the dose needed (ng/ml range) for the anti-fibrotic effect. We also revealed a complex regulatory network for GPNMB in dcSSc fibroblasts, as it appears to be suppressed by TGFβ.


Disclosures: P. Palisoc, None; L. Vaikutis, None; E. Model, None; M. Omara, None; D. Khanna, AbbVie, 2, Acceleron, 2, Actelion, 2, Amgen, 2, Bayer, 2, 5, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 5, CiviBioPharma/Eicos Sciences, Inc, 12, Leadership/Equity position (Chief Medical Officer), Corbus, 2, CSL Behring, 2, Eicos Sciences, Inc, 11, Galapagos NV, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon Therapeutics, 2, 5, Immune Tolerance Network, 5, Merck Sharp & Dohme, 2, Mitsubishi Tanabe Pharma, 2, National Institutes of Health, 5, Pfizer, 5, Sanofi-Aventis, 2, United Therapeutics, 2, Prometheus, 2, Theraly, 2, AstraZeneca, 2; E. Tsou, None; A. Sawalha, None.

To cite this abstract in AMA style:

Palisoc P, Vaikutis L, Model E, Omara M, Khanna D, Tsou E, Sawalha A. Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/functional-characterization-of-glycoprotein-nonmetastatic-melanoma-protein-b-in-scleroderma-fibrosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-characterization-of-glycoprotein-nonmetastatic-melanoma-protein-b-in-scleroderma-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology